### **Company Overview** Alivus Life Sciences Ltd is a leading Indian developer and manufacturer of **high-value, non-commoditized Active Pharmaceutical Ingredients (APIs)** focused on **chronic therapeutic areas** including cardiovascular (CVS), central nervous system (CNS), diabetes, oncology, pain, and urology. Formerly known as **Glenmark Life Sciences Limited (GLS)**, the company was acquired by **Nirma Limited** in March 2024 and rebranded as Alivus in December 2024, marking a strategic transformation into a **standalone, innovation-driven life sciences entity**. As a **pure-play API and CDMO (Contract Development and Manufacturing Organization)** company, Alivus serves over **700 customers** across more than **75 countries**, including **20 of the world’s largest generic pharmaceutical companies**. Its product portfolio comprises **165 molecules**, with **49 under active development**, including **24 High-Potency APIs (HPAPIs)** and **3 iron complexes**. The company is positioned as a trusted partner in **regulated markets**, offering end-to-end support across the product lifecycle. --- ### **Business Model & Strategic Positioning** - **B2B-Only Model**: Alivus operates exclusively on a B2B basis with no trading or third-party distributor networks, ensuring controlled, quality-driven supply to pharmaceutical formulators. - **Revenue Mix**: - **~85% from regulated markets** (US, Europe, Japan, Canada, etc.) - **~15% from emerging markets** - **Customer Stickiness**: Over **80% of clients are repeat customers**, with **long-term contracts** and multi-year relationships, including a major agreement with **Glenmark Pharma Limited (GPL)** and collaborations with innovator firms. - **CDMO Focus**: The CDMO segment is a strategic growth engine, particularly in **505(b)(2) pathways** and **post-patent lifecycle management**, leveraging process chemistry, analytical research, and regulatory filing expertise. --- ### **Product Portfolio & Market Opportunities** - **Current Portfolio**: - **165 marketed API molecules**, a diversification from 151 in FY24 - **Top 10 generic APIs contribute 45%** of revenue - Key molecules: **Sitagliptin, Rosuvastatin, Solifenacin, Cabozantinib, Palbociclib, Vonoprazan, Elacestrant, and Ensifentrine** - **Therapeutic Areas**: - Cardiovascular, CNS, diabetes, oncology, pain, urology, anti-fungals, anti-acne, immunomodulators, and ophthalmology - **Addressable Market**: - **$180 billion front-end market by 2026**, growing at **4.3% CAGR** - **API volume market expected to reach 13,609 tonnes by 2026**, growing at **6% annually** --- ### **Innovation & R&D Capabilities** - **R&D Investment**: INR 805 crores ($96M) in FY25, representing **3.4% of sales**, up from INR 400 crores in FY20 - **R&D Personnel**: 347 scientists (up from 236 in FY20), organized across **three advanced R&D centers** (Ankleshwar, Dahej, Mahape) - **Core Competencies**: - Polymorphism screening, cryogenics, enzymatic transformation, continuous flow chemistry, ultra-filtration, high-pressure hydrogenation - **Pipeline (as of Aug 2025)**: - **49 new products in development** - **24 HPAPIs** (7 validated, 5 in advanced development) - **3 iron complexes** (potential 2 more in pipeline) - Oncology pipeline: **12 APIs under development**, with exhibit batches supplied and significant future potential (~$45B market) - **Intellectual Property**: - **82 granted patents** (India, US, Europe) in process chemistry, novel polymorphs, and manufacturing - Emphasis on **patented synthetic routes** and **tech transfer protection** --- ### **Regulatory & Compliance Excellence** - **Global Regulatory Filings**: - **561 DMFs and CEPs** filed cumulatively as of March 2025, up from 520 in FY24 - High filings in CVS and CNS therapies - **Facility Inspections**: - Regular audits by **USFDA, PMDA (Japan), Swissmedic, EDQM (Europe), ANVISA (Brazil), and CDSCO (India)** - Recent successful inspections reinforce credibility in **regulated markets** --- ### **Manufacturing & Supply Chain Infrastructure** - **Production Capacity**: - **Four cGMP-compliant, multi-purpose facilities** in: - **Ankleshwar, Dahej (Gujarat)** - **Mohol, Kurkumbh (Maharashtra)** - **Total installed reactor capacity: 1,424 KL** - **Annual production volume: ~810 metric tonnes (FY25)**, targeting **>900 MT in FY26** - **Production Scalability**: - Flexible production from **gram to ton-scale** - Supports **small-volume, high-value** and **mid-volume APIs** - **Operational Excellence**: - **Commercial-scale continuous manufacturing** implemented, reducing effluent and improving throughput - **Green chemistry initiatives**: solvent recovery, waste reduction, renewable energy adoption - **Backward integration** into select **Key Starting Materials (KSMs)** in India and China, reducing input cost volatility - **Flow chemistry** integrated into production for complex and oncology APIs --- ### **Strategic Growth Initiatives (2025–2028)** Alivus is transitioning from consolidation to **accelerated expansion**, supported by a **capital-intensive growth phase** focused on **long-term capacity and capability build**. #### **1. Capacity Expansion** - **Solapur Greenfield Facility**: - Located in **Chincholi Industrial Area**, near 40-acre site - **Total planned capacity: 1,000 KL (1,000 MT)** - **Phases**: - **Phase 1 (200 KL)**: API capacity, operational by **Q4 FY26** - **Phase 1.1 (400 KL)**: KSM and intermediates, FY27 - **Phase 2 (400 KL)**: API capacity, FY28 - Environmental clearance secured - **Brownfield Expansions**: - **Ankleshwar**: +100 KL by FY26 - **Dahej**: +160 KL by FY26 - **Oncology-dedicated block** operational - **CAPEX Outlook**: - **INR 600 crore investment planned for FY26**, including **carryover of INR 190 crore** - Focus on **Solapur facility, R&D center, and facility upgrades** #### **2. R&D & Innovation Infrastructure** - **New R&D Centre Near Mumbai**: - Investment of **INR 800 million** - Focus: **flow chemistry, complex API development, oncology, pellets, analytical characterization** - **Enhanced Platforms**: - Dedicated focus on **oncology, HPAPIs, iron complexes, and 505(b)(2) CDMO projects** #### **3. CDMO Business Growth** - Key growth lever with **step-function revenue potential**: - Each project valued at **INR 50–60 crores ($7–8M)** - **Five active CDMO projects**, including **four with Japanese innovators** - Focus on **lifecycle management**, **complex generics**, and **specialty APIs** --- ### **Financial & Operational Highlights** - **Revenue Mix**: - **25–30% from US market** (stable and high-value segment) - Strong exports: **51.7% of turnover from international markets** - **Volume Growth**: - Mid-teens volume growth; expecting **high single-digit revenue growth** in near term - **Cost Leadership**: - **Cost Improvement Projects (CIPs)** on mature APIs to sustain margins - Adoption of **second/third-generation processes**, **debottlenecking**, and **automation** - **Efficiency Gains**: - Continuous manufacturing, solvent recovery, reduced carbon footprint - Implementation of **SAP S/4HANA** for enhanced analytics and agility --- ### **Ownership & Strategic Vision** - **Parent Company**: **Nirma Limited**, a diversified chemical and pharma conglomerate - **Leadership Focus**: - **Operational agility, innovation-led R&D, and strategic autonomy** - Disciplined capital allocation for **sustainable ROI and long-term stakeholder value** - **Public Listing**: Listed on **BSE and NSE** under both names (legacy GLS and Alivus), with strong retail investor base